Board Of Directors
Christina Herder
Chair of the Board
Christina Herder has experience from strategic leadership roles in drug development and partnering in the life science industry. Her operational assignments include several executive positions in companies like Sobi and Medivir. For more than 10 years, she has worked as board member in several Nordic biotech companies.
Tobhias Brandell
Board Member
Tobhias Brandell is a lawyer and partner at TM & Partners with a focus on financing and corporate law. He heads the firm’s finance team and his previous experience includes positions at leading law firms in Stockholm and London and as in-house counsel at a global financial institution.
Martin Bruce
Board Member
As a member of the founding family, Martin Bruce brings a unique blend of business acumen and linguistic proficiency, having studied in France. His international experience, including time spent in Italy and the UAE, has provided him with valuable insights into diverse business environments.
Martin has actively participated in various startups and ventures, and at TikoMed, he has played a pivotal role in leveraging his extensive network to attract investors and key talent, driving the company’s growth.
Annika Kollén
Board Member
Annika Kollén is currently the COO of Inceptua, a pharma services company with a global footprint. Before joining Inceptua, she was the Head of Global Supply Chain & Procurement at Sobi, a Swedish rare disease company, and has also held various management roles at Novartis.
Anders Svensson
Board Member
Anders Svensson, MD PhD, is a cardiologist and Associate Professor with more than 25 years' experience from senior global roles in the pharmaceutical industry at AstraZeneca and Roche. He is now an independent consultant and holds several board positions in emerging biotech companies.
Juan Vergez
Board member
Juan Vergez is a seasoned life sciences executive with a strong track record in pharmaceutical industry commercial strategy, operational execution, and advancing clinical-stage products into commercial stage. He has led growth and transformation initiatives across healthcare and biotechnology companies, combining strategic leadership with hands-on expertise in rare disease and specialty product launches, business development, partnerships, financing, and market expansion.
